|
業務類別
|
-- |
|
業務概覽
|
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease. |
| 公司地址
| Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB |
| 電話號碼
| +31 107038441 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.argenx.com |
| 員工數量
| 2373 |
| Dr. Luc Truyen, M.D.,PhD |
Chief Medical Officer |
-- |
20/03/2025 |
| Dr. Peter Ulrichts |
Chief Scientific Officer |
-- |
20/03/2025 |
| Mr. Tim Van Hauwermeiren, M. Sc. |
Executive Director and Chief Executive Officer |
美元 757.68K |
20/03/2025 |
| Mr. Arjen Lemmen |
Vice President, Corporate Development and Strategy |
-- |
20/03/2025 |
| Ms. Andria Wilk |
Global Head, Quality |
-- |
20/03/2025 |
| Ms. Karen Massey |
Chief Operating Officer |
美元 655.66K |
20/03/2025 |
| Mr. Karl Gubitz |
Chief Financial Officer |
美元 553.00K |
20/03/2025 |
| Ms. Malini Moorthy |
General Counsel |
-- |
20/03/2025 |
|
|
| Mr. James M. Daly |
Independent Director |
20/03/2025 |
| Mr. Tim Van Hauwermeiren, M. Sc. |
Executive Director and Chief Executive Officer |
20/03/2025 |
| Mr. Peter K.M. Verhaeghe |
Non-Executive Chairman of the Board |
20/03/2025 |
| Dr. J. Donald deBethizy, PhD |
Independent Director |
20/03/2025 |
| Dr. Pamela M. Klein, M.D. |
Independent Director |
20/03/2025 |
| Mr. Anthony A. Rosenberg |
Independent Director |
20/03/2025 |
| Dr. Brian L. Kotzin, M.D. |
Independent Director |
20/03/2025 |
| Mr. Steven E. Krognes, M.B.A. |
Independent Director |
20/03/2025 |
| Ms. Camilla Sylvest |
Independent Director |
20/03/2025 |
| Dr. Ana Cespedes, PhD |
Independent Director |
20/03/2025 |
|
|
|
|
